Patrick S Ramsey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3647340/publications.pdf

Version: 2024-02-01

97 papers

2,951 citations

147566 31 h-index 51 g-index

100 all docs

 $\begin{array}{c} 100 \\ \\ \text{docs citations} \end{array}$

100 times ranked

2679 citing authors

#	Article	IF	CITATIONS
1	Whole blood transfusion reduces overall component transfusion in cases of placenta accreta spectrum: a pilot program. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 6455-6460.	0.7	14
2	Neuraxial to general anesthesia conversion has equitable intraoperative and improved post-operative outcomes compared to general anesthesia in cesarean hysterectomy for placenta accreta spectrum (PAS). Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 8640-8644.	0.7	3
3	Fetal Intervention for Refractory Supraventricular Tachycardia Complicated by Hydrops Fetalis. Case Reports in Obstetrics and Gynecology, 2022, 2022, 1-4.	0.2	3
4	Effect of anesthesia selection on neonatal outcomes in cesarean hysterectomies for placenta accreta spectrum (PAS). Journal of Perinatal Medicine, 2022, 50, 1210-1214.	0.6	2
5	Maternal morbidity by attempted route of delivery in periviable birth. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 1241-1248.	0.7	3
6	Effect of virtual interviewing on applicant approach to and perspective of the Maternal-Fetal Medicine Subspecialty Fellowship Match. American Journal of Obstetrics & Subspecialty Fellowship Match. American Journal of Obstetrics & Subspecialty Fellowship Match. American Journal of Obstetrics & Subspecialty Fellowship Match.	1.3	12
7	Maternal-fetal medicine program director experience of exclusive virtual interviewing during the coronavirus disease 2019 pandemic. American Journal of Obstetrics & Synecology MFM, 2021, 3, 100344.	1.3	5
8	Maternal comorbidity index and severe maternal morbidity during delivery hospitalizations in Texas, 2011â€2014. Birth, 2020, 47, 89-97.	1.1	5
9	Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology. The Cochrane Library, 2019, 2019, .	1.5	26
10	In Reply. Obstetrics and Gynecology, 2019, 133, 385-385.	1.2	2
11	Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology. The Cochrane Library, 2018, 10, CD003511.	1.5	46
12	Adjuvant Use of Rifampin for Refractory Intrahepatic Cholestasis of Pregnancy. Obstetrics and		
	Gynecology, 2018, 132, 678-681.	1.2	17
13	Cynecology, 2018, 132, 678-681. Intra-amniotic Dye Alternatives for the Diagnosis of Preterm Prelabor Rupture of Membranes. Obstetrics and Gynecology, 2017, 129, 1040-1045.	1.2	12
13 14	Intra-amniotic Dye Alternatives for the Diagnosis of Preterm Prelabor Rupture of Membranes.		
	Intra-amniotic Dye Alternatives for the Diagnosis of Preterm Prelabor Rupture of Membranes. Obstetrics and Gynecology, 2017, 129, 1040-1045.	1.2	12
14	Intra-amniotic Dye Alternatives for the Diagnosis of Preterm Prelabor Rupture of Membranes. Obstetrics and Gynecology, 2017, 129, 1040-1045. What Is New in Zika Virus in Pregnancy?. Obstetrics and Gynecology, 2017, 130, 213-214. Glycemic control, compliance, and satisfaction for diabetic gravidas in centering group care. Journal	1.2	0
14 15	Intra-amniotic Dye Alternatives for the Diagnosis of Preterm Prelabor Rupture of Membranes. Obstetrics and Gynecology, 2017, 129, 1040-1045. What Is New in Zika Virus in Pregnancy?. Obstetrics and Gynecology, 2017, 130, 213-214. Glycemic control, compliance, and satisfaction for diabetic gravidas in centering group care. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 1221-1226. Efficiency of Screening for the Recurrence of Antenatal Group B Streptococcus Colonization in a Subsequent Pregnancy: A Systematic Review and Meta-analysis with Independent Patient Data. American	1.2 1.2 0.7	12 O 15

#	Article	IF	CITATIONS
19	Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. American Journal of Obstetrics and Gynecology, 2015, 213, 570.e1-570.e8.	0.7	89
20	Outcomes of Triplets Reduced to Twins Versus Non-Reduced Triplet Pregnancies. Journal of Clinical Gynecology and Obstetrics, 2015, 4, 160-163.	0.1	10
21	First trimester screening cannot predict adverse outcomes yet. Prenatal Diagnosis, 2014, 34, 668-676.	1.1	21
22	Prevalence of Group B Streptococcus Colonization in Subsequent Pregnancies of Group B Streptococcus-Colonized versus Noncolonized Women. American Journal of Perinatology, 2013, 30, 383-388.	0.6	9
23	Progestogen for preventing miscarriage. The Cochrane Library, 2013, , CD003511.	1.5	43
24	Spontaneous Uterine Rupture in Pregnancy After Endometrial Ablation. Obstetrics and Gynecology, 2010, 115, 405-406.	1.2	12
25	Medication effects on midtrimester maternal serum screening. American Journal of Obstetrics and Gynecology, 2009, 201, 622.e1-622.e5.	0.7	5
26	Progestogen for preventing miscarriage. , 2008, , CD003511.		61
27	Is there a preferred gestational age threshold of viability?: A survey of maternal-fetal medicine providers. Journal of Maternal-Fetal and Neonatal Medicine, 2007, 20, 293-297.	0.7	12
28	Transcervical Foley Catheter With and Without Extraamniotic Saline Infusion for Labor Induction. Obstetrics and Gynecology, 2007, 110, 558-565.	1.2	82
29	Usage of spot urine protein to creatinine ratios in the evaluation of preeclampsia. American Journal of Obstetrics and Gynecology, 2007, 196, 465.e1-465.e4.	0.7	40
30	Prophylactic subcutaneous drainage for prevention of wound complications after cesarean delivery—a metaanalysis. American Journal of Obstetrics and Gynecology, 2007, 197, 229-235.	0.7	78
31	Impact of Anomalous Triplets on Morbidity Outcomes of Normal In Utero Siblings. Obstetrics and Gynecology, 2006, 107, 1352-1356.	1.2	3
32	The scope of duty hour–associated residency structure modifications. American Journal of Obstetrics and Gynecology, 2006, 194, 282-288.	0.7	9
33	The perceived impact of duty hour restrictions on the residency environment: A survey of residency program directors. American Journal of Obstetrics and Gynecology, 2006, 194, 1556-1562.	0.7	11
34	Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. American Journal of Obstetrics and Gynecology, 2006, 194, 774-781.	0.7	83
35	Corticosteroids and HELLP. American Journal of Obstetrics and Gynecology, 2006, 195, e7.	0.7	2
36	Preterm Premature Rupture of Membranes: Is There an Optimal Gestational Age for Delivery?. Obstetrics and Gynecology, 2005, 105, 1485-1486.	1.2	0

#	Article	IF	CITATIONS
37	Subcutaneous Tissue Reapproximation, Alone or in Combination With Drain, in Obese Women Undergoing Cesarean Delivery. Obstetrics and Gynecology, 2005, 105, 967-973.	1.2	103
38	Misoprostol for Labor Induction in Women With Term Premature Rupture of Membranes. Obstetrics and Gynecology, 2005, 106, 593-601.	1.2	98
39	Preterm Premature Rupture of Membranes: Is There an Optimal Gestational Age for Delivery?. Obstetrics and Gynecology, 2005, 105, 12-17.	1.2	48
40	Use of Vaginal Polymorphonuclear to Epithelial Cell Ratios for the Prediction of Preterm Birth. Obstetrics and Gynecology, 2005, 105, 139-144.	1.2	17
41	Midtrimester amniotic fluid matrix metalloproteinase-8 (MMP-8) levels above the 90th percentile are a marker for subsequent preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology, 2005, 192, 109-113.	0.7	49
42	Chorioamnionitis increases neonatal morbidity in pregnancies complicated by preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology, 2005, 192, 1162-1166.	0.7	162
43	Comparative longitudinal study of cervical length and induced shortening changes among singleton, twin, and triplet pregnancies. American Journal of Obstetrics and Gynecology, 2005, 192, 1410-1415.	0.7	30
44	Biochemical markers for the prediction of preterm birth. American Journal of Obstetrics and Gynecology, 2005, 192, S36-S46.	0.7	148
45	Spontaneous epidural hematoma of the spine in pregnancy. American Journal of Obstetrics and Gynecology, 2005, 193, 875-877.	0.7	61
46	High-dose vaginal misoprostol versus concentrated oxytocin plus low-dose vaginal misoprostol for midtrimester labor induction: A randomized trial. American Journal of Obstetrics and Gynecology, 2005, 193, 1065-1070.	0.7	27
47	Preterm Premature Rupture of Membranes: Perspectives Surrounding Controversies in Management. American Journal of Perinatology, 2005, 22, 287-297.	0.6	35
48	Cardiotocographic Abnormalities Associated With Dinoprostone and Misoprostol Cervical Ripening. Obstetrics and Gynecology, 2005, 105, 85-90.	1.2	31
49	Carnitine palmitoyltransferase deficiency in pregnancy. Journal of Maternal-Fetal and Neonatal Medicine, 2005, 18, 357-359.	0.7	11
50	The relationship between practice setting and management of preterm premature rupture of membranes. Journal of Maternal-Fetal and Neonatal Medicine, 2005, 18, 53-57.	0.7	1
51	A Prospective Trial of Elective Preterm Delivery for Fetal Gastroschisis. American Journal of Perinatology, 2004, 21, 289-294.	0.6	80
52	Vaginal Misoprostol Versus Concentrated Oxytocin and Vaginal PGE2 for Second-Trimester Labor Induction. Obstetrics and Gynecology, 2004, 104, 138-145.	1.2	31
53	Umbilical cord plasma interleukin-6 concentrations in preterm infants and risk of neonatal morbidity. American Journal of Obstetrics and Gynecology, 2004, 191, 1375-1381.	0.7	123
54	Contemporary management of preterm premature rupture of membranes (PPROM): A survey of maternal-fetal medicine providers. American Journal of Obstetrics and Gynecology, 2004, 191, 1497-1502.	0.7	73

#	Article	IF	CITATIONS
55	Intrapartum management of multifetal pregnancies. Seminars in Perinatology, 2003, 27, 54-72.	1.1	18
56	Maternal and transplacental pharmacokinetics of azithromycin. American Journal of Obstetrics and Gynecology, 2003, 188, 714-718.	0.7	83
57	Comparative efficacy and cost of the prostaglandin analogs dinoprostone and misoprostol as labor preinduction agents. American Journal of Obstetrics and Gynecology, 2003, 188, 560-565.	0.7	36
58	Biochemical predictors of preterm labor: fetal fibronectin and salivary estriol. Clinics in Perinatology, 2003, 30, 701-733.	0.8	40
59	Characterization of the relationship between joint laxity and maternal hormones in pregnancy. Obstetrics and Gynecology, 2003, 101, 331-335.	1.2	111
60	A Guest Editorial: Stump the Professor. Obstetrical and Gynecological Survey, 2002, 57, 785-787.	0.2	0
61	Treatment of Syphilis in Pregnancy and Prevention of Congenital Syphilis. Clinical Infectious Diseases, 2002, 35, S200-S209.	2.9	120
62	Pneumoamnion and pregnancy loss after second-trimester laparoscopic surgery. Obstetrics and Gynecology, 2002, 99, 512-513.	1.2	76
63	Therapies administered to mothers at risk for preterm birth and neurodevelopmental outcome in their infants. Clinics in Perinatology, 2002, 29, 725-743.	0.8	9
64	High-Dose Oral Misoprostol for Mid-Trimester Pregnancy Interruption. Gynecologic and Obstetric Investigation, 2002, 54, 176-179.	0.7	26
65	The Preterm Prediction Study: Elevated cervical ferritin levels at 22 to 24 weeks of gestation are associated with spontaneous preterm delivery in asymptomatic women. American Journal of Obstetrics and Gynecology, 2002, 186, 458-463.	0.7	35
66	Effect of vaginal pH on efficacy of the dinoprostone gel for cervical ripening/labor induction. American Journal of Obstetrics and Gynecology, 2002, 187, 843-846.	0.7	19
67	Gestational Trophoblastic Disease: Another Cause of Nausea and Vomiting in Pregnancy: In Response. Mayo Clinic Proceedings, 2001, 76, 566.	1.4	0
68	DISEASE OF THE GALLBLADDER AND PANCREAS IN PREGNANCY. Obstetrics and Gynecology Clinics of North America, 2001, 28, 571-580.	0.7	62
69	Lethal pulmonary hypoplasia after in-utero myelomeningocele repair. Obstetrics and Gynecology, 2001, 98, 698-701.	1.2	3
70	PNEUMONIA IN PREGNANCY. Obstetrics and Gynecology Clinics of North America, 2001, 28, 553-569.	0.7	74
71	Magnesium sulfate as a tocolytic agent. Seminars in Perinatology, 2001, 25, 236-247.	1.1	37
72	Delayed postpartum hemorrhage: A rare presentation of carbon monoxide poisoning. American Journal of Obstetrics and Gynecology, 2001, 184, 243-244.	0.7	7

#	Article	IF	CITATIONS
73	In utero erythrocyte transfusion for fetal xerocytosis associated with severe anemia and non-immune hydrops fetalis. American Journal of Obstetrics and Gynecology, 2001, 185, 238-239.	0.7	10
74	Cardiac Disease in Pregnancy. American Journal of Perinatology, 2001, 18, 245-266.	0.6	20
75	Labor induction. Current Opinion in Obstetrics and Gynecology, 2000, 12, 463-473.	0.9	30
76	Artifactual fetal electrocardiographic detection using internal monitoring following intrapartum fetal demise during VBAC trial. The Journal of Maternal-fetal Medicine, 2000, 9, 360-361.	0.2	8
77	Malignant pleural mesothelioma in pregnancy. The Journal of Maternal-fetal Medicine, 2000, 9, 373-375.	0.2	1
78	Effect of vaginal pH on efficacy of misoprostol for cervical ripening and labor induction. American Journal of Obstetrics and Gynecology, 2000, 182, 1616-1619.	0.7	26
79	Cardiovascular effects of intravaginal misoprostol in the mid trimester of pregnancy. American Journal of Obstetrics and Gynecology, 2000, 183, 1100-1102.	0.7	22
80	Malignant pleural mesothelioma in pregnancy. Journal of Maternal-Fetal and Neonatal Medicine, 2000, 9, 373-375.	0.7	0
81	Syphilis in pregnancy: a review. Primary Care Update for Ob/Gyns, 2000, 7, 26-30.	0.1	8
82	Artifactual fetal electrocardiographic detection using internal monitoring following intrapartum fetal demise during VBAC trial. Journal of Maternal-Fetal and Neonatal Medicine, 2000, 9, 360-361.	0.7	0
83	34-Year-Old Year-Old Pregnant Woman With Nausea and Vomiting. Mayo Clinic Proceedings, 2000, 75, 1317-1320.	1.4	3
84	Artifactual fetal electrocardiographic detection using internal monitoring following intrapartum fetal demise during VBAC trial. The Journal of Maternal-fetal Medicine, 2000, 9, 360-361.	0.2	5
85	Midtrimester Cervical Ripening and Labor Induction. Clinical Obstetrics and Gynecology, 2000, 43, 495-512.	0.6	15
86	Ultrasonographic assessment of cervical length in triplet pregnancies. American Journal of Obstetrics and Gynecology, 1999, 180, 1442-1445.	0.7	42
87	Acute pancreatitis after gynecologic and obstetric surgery. American Journal of Obstetrics and Gynecology, 1999, 181, 542-546.	0.7	12
88	Misoprostol as a labor induction agent. , 1998, 7, 15-18.		14
89	Successful pregnancy following orthotopic liver transplantation for idiopathic Budd-Chiari Syndrome., 1998, 7, 235-237.		7
90	Successful pregnancy following orthotopic liver transplantation for idiopathic budd-chiari syndrome. Journal of Maternal-Fetal and Neonatal Medicine, 1998, 7, 235-237.	0.7	1

#	Article	IF	CITATIONS
91	Misoprostol as a Labor Induction Agent. Journal of Maternal-Fetal and Neonatal Medicine, 1998, 7, 15-18.	0.7	1
92	Misoprostol as a labor induction agent. , 1998, 7, 15.		3
93	Misoprostol, a Prostaglandin, E1 analog, for prelabour ripening of the unfavourable uterine cervix. Fetal and Maternal Medicine Review, 1996, 8, 217-227.	0.3	11
94	Microvascular expression of mala-2 correlates within vivo lymphocyte trafficking and is preferentially enhanced in tumors by tumor necrosis factor- \hat{l}_{\pm} and interleukin- $1\hat{l}_{\pm}$. International Journal of Cancer, 1994, 59, 639-645.	2.3	3
95	Cell Adhesion Molecule Expression within the Microvasculature of Human Colorectal Malignancies. Clinical Immunology and Immunopathology, 1994, 72, 129-136.	2.1	32
96	Anti-tumor $\tilde{A}-$ anti-lymphocyte heteroconjugates augment colon tumor cell lysis in Vitro and prevent tumor growth in Vivo. Diseases of the Colon and Rectum, 1991, 34, 140-147.	0.7	9
97	Correlation of clinical outcomes with the application of the 2020 consensus panel on histological classification for Placenta Accreta Spectrum (PAS). Journal of Maternal-Fetal and Neonatal Medicine, 0, , 1-5.	0.7	O